Feasibility · NSCLC · Phase II–III
Non-small-cell lung cancer (NSCLC) trial feasibility, cited to its source.
NSCLC is one of the most actively studied indications, with feasibility dominated by molecular sub-segmentation (EGFR, ALK, KRAS G12C, PD-L1 status). The practical question is rarely "how many lung-cancer patients" but "how many of the right molecular subtype are reachable at non-saturated sites."
Deterministic, re-runnable feasibility scoring.
What drives feasibility here
The questions that decide go or no-go.
The traps that are specific to nsclc — the ones a generic prevalence estimate will miss.
Benchmarks · snapshot 2026-06-14
The numbers, each cited.
Counted from the public registry on the snapshot date below. Re-run the same query and you get the same figure.
1,071
Recruiting interventional trials, worldwide
Source: ClinicalTrials.gov — cond: NSCLC, interventional, recruiting
493
Recruiting interventional trials, United States
Source: ClinicalTrials.gov — cond: NSCLC, interventional, recruiting, US
7,045
Interventional trials registered, all statuses
Source: ClinicalTrials.gov — cond: NSCLC, interventional
Registry counts move. These are the figures as at the snapshot date; a live run re-counts them and stamps its own.
Grounded in public data
Where the nsclc read comes from.
Every figure links back to its source record with a snapshot date, so your team and the sponsor can re-verify it. Probability-of-success reads are directional — priors drawn from public precedent, not calibrated predictions — and are labelled that way in the verdict.
Also searched as: NSCLC trials, lung cancer feasibility.
See a cited verdict for nsclc.
Send us a protocol — or just a molecule and an indication. We'll return a fully cited feasibility assessment you can trace, line by line, back to public data — yours to defend in a bid, take to your board or investment committee, or hand to a regulator.